Navigation Links
Dana-Farber: Study reports first success of targeted therapy in type of non-small cell lung cancer
Date:5/31/2012

BOSTONA novel compound has become the first targeted therapy to benefit patients with the most common genetic subtype of lung cancer, an international clinical trial led by scientists at Dana-Farber Cancer Institute and other institutions will report at the annual meeting of the American Society of Clinical Oncology (ASCO) June 1-5 in Chicago.

Pasi A. Jnne, MD, PhD, scientific co-director of Dana-Farber's Belfer Institute for Applied Cancer Science, will present the findings from the randomized phase II study (abstract 7503) on Monday, June 4, 3 p.m. CT, E Hall D2, McCormick Place.

The study involved 87 non-small cell lung cancer (NSCLC) patients whose tumors carry a mutation in the gene KRAS. Such tumors account for about 20 percent of NSCLC cases, but no targeted therapy has proved effective against them in previous clinical research. The drug under investigation, selumetinib, doesn't attack KRAS directly, but interferes with one of its molecular henchmen, a protein called MEK.

Participants in the study all had advanced stages of the disease. They received the standard chemotherapy agent docetaxel in combination with either selumetinib or a placebo.

By many measures the rate and duration of response to treatment, change in tumor size, and proportion of patients alive and showing no signs of advancing disease -- the group receiving selumetinib did significantly better than the other group. Most clinically significant were the improved rate of response to treatment (37 percent compared to 0 percent in the placebo arm) and prolonged progression-free survival (5.3 months compared to 2.1 months in the placebo arm). Although patients in the selumetinib group survived longer, on average, than those in the placebo group 9.4 months compared to 5.2 months the improvement was not considered statistically significant.

"This clinical trial demonstrates that a combination of chemotherapy and selumetinib is significantly better than chemotherapy alone for this group of patients better in terms of tumor response to therapy and in terms of survival times prior to advance of the disease," says Jnne. "It suggests that for the first time we may have an effective treatment for KRAS-mutant lung cancer, which is the largest single subtype of the disease. These impressive clinical findings not only have implications for the treatment of lung cancer but all cancers that harbor KRAS mutations, including pancreatic and colorectal cancer."

Some side effects, such as neutropenia (a white blood cell deficiency), loss of strength, acne, and respiratory problems were more common in the selumetinib group than the other, but the rate of patients dropping out of the study because of severe side effects was similar for both groups.


'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. Humans Can Sniff Out Old Age in Others, Study Shows
2. Infant Smarts Similar With Different Types of Formula: Study
3. Pre-op Treatments Boost Survival for Esophageal Cancer Patients: Study
4. Cooling Helps Oxygen-Deprived Newborns: Study
5. Immigrant women giving birth in Spain suffer great stress, a study warns
6. Once-Obese Women Still Face Stigma, Study Finds
7. Surly People Tend to Like Fierce Dogs, Study Shows
8. Nordic Walking a Winner for Heart Failure Patients, Study Says
9. Common Painkillers May Help Prevent Skin Cancer: Study
10. Antioxidant shows promise as treatment for certain features of autism, Stanford study finds
11. Tight Blood-Sugar Control Shows Mixed Results for Health of Kidneys: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2020)... ... July 02, 2020 , ... Temprian, ... of autoimmune diseases. Its lead indication is vitiligo. Vitiligo patients develop progressive ... , While vitiligo is equally prevalent in all ethnic groups, it ...
(Date:7/2/2020)... SHELTON, Conn. (PRWEB) , ... July 02, 2020 ... ... closure of many businesses, including dental offices for non-emergency work. In conjunction with ... released reopening guidelines for Connecticut dental practices in mid-May. , Due to ...
(Date:7/1/2020)... ... July 01, 2020 , ... The Society to Improve Diagnosis ... at the University of Massachusetts Medical School- Baystate and Ann Gaffey, RN, MSN, ... Board of Directors. Dr. Salvador and Ms. Gaffey’s service began in May and ...
(Date:6/28/2020)... ... , ... PathAI, a global provider of artificial intelligence (AI)-powered technology for use ... of PD-L1 expression to assess response in patients treated with Bristol Myers Squibb’s PD-1 ... Cancer Research (AACR) Annual Meeting. AACR was held June 22 to June 24. , ...
(Date:6/28/2020)... , ... June 27, 2020 , ... ... Classroom, the first online, full-day educational conference in the organization’s history. The online ... facioscapulohumeral muscular dystrophy (FSHD), which was cancelled this year due to COVID-19. Nearly ...
Breaking Medicine News(10 mins):
(Date:7/7/2020)... ... July 07, 2020 , ... With ... Navajo Nation residents, the 33 nonprofits who received the latest ISA Foundation ... round of funding, the foundation awarded grants totaling $838,527 to the U.S.-based 501(c)(3) ...
(Date:7/4/2020)... , ... July 03, 2020 , ... By Heidi Jean ... we’ve retreated into our homes for cover, Assuaged, Inc. is going full ... all over the globe this year to get their feet wet in marketing, social ...
(Date:7/2/2020)... ... July 02, 2020 , ... Realty ONE Group ... health series on its live agent Town Halls, furthering its commitment to its ... series includes special guests and Realty ONE Group leadership discussing social, mental, physical ...
Breaking Medicine Technology: